|
|
News Breaks | | | | December 31, 2012 | | 16:09 EDT |  | JNJ, CG, BMY, COV, DUF, WPI, PFE | On The Fly: Closing Wrap
Stocks on Wall Street advanced on the last day of the year as a fiscal cliff deal appeared to be near, though one has yet to be taken up for a vote in the Senate, let alone sent to the House. The averages began a move higher following news that President Obama would speak at the White House at 1:30. The markets sold off a bit following Obama's remarks, but Senate Minority Leader Mitch McConnell's statement that the two sides were "very close" to a deal sent the averages higher once again... ECONOMIC EVENTS: In the U.S. a minor economic report, the Dallas Fed's December manufacturing survey, came in better than expected at +6.8. In China, the HSBC purchasing managers’ index for December rose to a final reading of 51.5, an upward revision from the preliminary 50.9 result and an improvement from 50.5 a month earlier... COMPANY NEWS: After Friday's closing bell, the FDA announced it had approved the anti-clotting drug Eliquis, marketed by Bristol-Myers Squibb (BMY) and Pfizer (PFE). Atlantic Equities upgraded Bristol-Myers citing the approval and shares advanced 69c, or 2.16%, to $32.59. Pfizer shares gained 19c, or 0.76%, to $25.08... MAJOR MOVERS: Among the notable gainers was Duff & Phelps (DUF), up $2.57, or 19.69%, to $15.62 after agreeing to be acquired by a group led by The Carlyle Group (CG) for $15.55, with the provision that Duff & Phelps can continue to seek a better deal. Among the noteworthy losers was Watson Pharma (WPI), down $3.04, or 3.41%, to $86.00 after Covidien's (COV) pharmaceutical unit was granted clearance to market a generic version of Concerta, which will compete with Watson's generic offering of the Janssen (JNJ) drug... INDICES: The Dow was up 166.03, or 1.28%, to 13,104.14; the Nasdaq was up 59.20, or 2.00%, to 3,019.51; and the S&P 500 was up 23.77, or 1.69%, to 1,426.20. | |
|
News For BMY;PFE;DUF;CG;WPI;COV;JNJ From The Last 14 Days Check below for free stories on BMY;PFE;DUF;CG;WPI;COV;JNJ the last two weeks. |
|
|
| June 19, 2013 | | 08:45 EDT |  | JNJ | Leerink's biotech analyst holds analyst/industry conference call on ADA
Analyst Antlaffy, along with Dr. George Grunberger, founder & Chairman of the Grunberger Diabetes Institute, preview the upcoming American Diabetes Association's conference, including perspectives on new devices in diabetes, potential disruptive technologies at ADA and progress towards the artificial pancreas on an Analyst/Industry conference call to be held on June 20 at 2 pm. | | | 07:41 EDT |  | PFE | Pfizer holders should consider Zoetis exchange, says BMO Capital
BMO Capital thinks Pfizer (PFE) investors should consider participating in the Zoetis (ZTS) exchange as they have the opportunity to own Zoetis at around $29.40-$29.70 per share, which is 15% below BMO's valuation of $34 per share. Further, BMO thinks there is strong support for Zoetis below $30, which the firm feels lowers downside risk. BMO recommends that Pfizer investors tender around 20% of their shares into the exchange, noting that with the offer likely being oversubscribed, not all tendered shares will be converted to Zoetis. | | | 05:43 EDT |  | BMY | AstraZeneca, Bristol-Myers announce top line results of Phase 4 trial of Onglyza
 Subscribe for More Information | | | June 18, 2013 | | 09:38 EDT |  | PFE | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM | | | 07:34 EDT | | JNJ | Medivation pullback a buying opportunity, says JPMorgan
Subscribe for More Information | | | June 17, 2013 | | 19:54 EDT |  | CG | Carlyle Group COO buys $4M in secondary, Barron's says
Subscribe for More Information | | | 16:20 EDT | | JNJ | On The Fly: Closing Wrap
Stocks on Wall Street were higher following a session dominated by speculation over what is next for the Federal Reserve. The averages trimmed their gains after an article by the Financial Times suggested the Fed would signal a tapering of its pace of asset purchases at its Wednesday press conference. The upward trend resumed after the article's author said the report was based on opinion and that, "The Fed does not leak anything to any journalist to steer markets - especially during blackout." ECONOMIC EVENTS: In the U.S., the New York Fed Empire State Survey for June came in at 7.40, versus expectations for a 0 reading. The NAHB housing market confidence index for June rose to 52, versus the forecast for a more modest climb to 45 from its prior 44 reading. In Europe, Germany's Bundesbank said economic indicators for April pointed to robust growth in the second quarter and business sentiment improved in May, though warned of signs that growth in Europe's largest economy would slow over the summer. COMPANY NEWS: Netflix (NFLX) and DreamWorks (DWA) both climbed after announcing a major content deal. Under the agreement, DreamWorks will provide over 300 hours of content to Netflix, which the TV and movie service expects to start broadcasting next year. After the announcement, Netflix rose $15.24, or 7.12%, to $229.23, while DreamWorks added 93c, or 4.08%, to $23.74. MAJOR MOVERS: Among the notable gainers was Kandi Technologies (KNDI), up $1.53, or 24.4%, to $7.80 after saying it will deploy 5K-10K pure electric vehicles in China within the first year of launch. Also higher were shares of ViroPharma (VPHM), up $1.71, or 6.3%, to $28.87 after Reuters said the company has attracted takeover interest, though the company is not pursuing a sale. Among the noteworthy losers was Terex (TEX), down $2.45, or 7.72%, to $29.29 after the company lowered it fiscal year earnings view. Also lower was Medivation (MDVN), down $3.45, or 6.78%, to $47.41 after Johnson & Johnson (JNJ) acquired the company's competitor, privately held Aragon Pharmaceuticals. INDICES: The Dow was up 109.67, or 0.73%, to 15,179.85; the Nasdaq was up 28.57, or 0.83%, to 3,452.13; and the S&P 500 was up 12.31, or 0.76%, to 1,639.04. | | | 16:00 EDT | | PFE | Options Update; June 17, 2013
Subscribe for More Information | | | 12:29 EDT | | JNJ | On The Fly: Midday Wrap
Subscribe for More Information | | | 12:28 EDT | | JNJ | Medivation retreats after J&J beefs up prostate cancer slate
Subscribe for More Information | | | | 12:08 EDT | | JNJ | J&J deal not negative for Medivation, says Citigroup
Subscribe for More Information | | | 08:36 EDT | | PFE | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. | | | 08:04 EDT | | JNJ | Johnson & Johnson agrees to acquire Aragon Pharmaceuticals
Johnson & Johnson announced a definitive agreement to acquire Aragon Pharmaceuticals, a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer. Under the terms of the agreement, Johnson & Johnson will make an upfront cash payment of $650M, plus additional contingent payments of up to $350M based on reaching predetermined milestones. The transaction is expected to close in the third quarter of 2013. | | | 07:28 EDT | | BMY, PFE | Cambridge Healthtech Institute to host a conference
Subscribe for More Information | | | 07:02 EDT | | COV | Covidien announces publication of final results of Pipeline study
Covidien announced that the final results of the PUFs, Pipeline for Uncoilable or Failed Aneurysms, clinical study of its Pipeline embolization device have been published in the June issue of Radiology, the official peer-reviewed medical journal of the Radiological Society of North America. The Pipeline device met the trial’s primary endpoints for both effectiveness and safety. Based on these data, the Pipeline device was approved by the U.S. Food and Drug Administration on April 6, 2011. | | | June 16, 2013 | | 14:45 EDT | | JNJ | J&J's Depuy Synthes unit wins $16M in patent case, Bloomberg says
Subscribe for More Information | | | June 14, 2013 | | 16:00 EDT | | PFE | Options Update; June 14, 2013
Subscribe for More Information | | | 15:49 EDT | | JNJ | J&J's Mentor gets FDA approval for MemoryShape breast implants
Mentor Worldwide announced earlier the U.S. Food and Drug Administration has approved MENTOR MemoryShape breast implants. The open-label, multi-center MENTOR MemoryShape Breast Implant Core Study showed the implants were safe and effective in both reconstruction and augmentation patients at 6 years, with a low rate of adverse events, such as rupture and capsular contracture Baker grades III and IV. Post approval studies will be conducted to collect additional clinical data for the MemoryShape implants. Mentor joined the Johnson & Johnson family of companies in 2009 and is part of its Global Surgery Group. | | | 10:39 EDT | | CG | Firms looking to take HD Supply public at lower valuation, NY Times says
Subscribe for More Information | | | 09:03 EDT | | BMY | Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions
AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, June 21-25. The data include studies from five marketed products as well as dapagliflozin, an investigational compound in the U.S., currently approved for use in the European Union, Australia, New Zealand and Mexico. Key presentations include: the first presentation of Phase IIa pilot data exploring the use of dapagliflozin in adult patients with type 1 diabetes; four-year data examining the durability of dapagliflozin vs. glipizide as add-on therapies in patients with type 2 diabetes inadequately controlled on metformin; study evaluating the efficacy and tolerability of saxagliptin in patients with type 2 diabetes and a history of cardiovascular disease; three-year data from a study examining the effect of exenatide once weekly on sustained glycemic control and weight compared with insulin glargine; and Phase IV study examining glycemic control, weight, and hypoglycemia with exenatide compared to mealtime administration of rapid-acting analog insulin. | | |
|
|
|
|
|
|
